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ABSTRACT
Aim: The aim was to assess the effect of renal angioplasty with stent on systolic, diastolic, and mean arterial 
blood pressure (MAP) in awake and sleep time with ambulatory blood pressure (ABP) monitoring (Holter 
monitoring). Materials and Methods Patients with angiographically proven atherosclerotic renal artery stenosis 
(RAS) were referred to the Angiography Department of Imam Hospital for intervention during a 1-year period 
from June 2008 to December 2009. Primary stent placement was attempted by a single operator in 27 severe 
RAS cases although 1 case was omitted from the study because of technical failure. Pre- and postprocedure 
creatinine levels, ejection fraction (EF), history of diabetes mellitus (DM), and ABP were obtained. Twenty-six 
(17 men, 9 women; average age, 62.6 years; age range, 90–21 years) consecutive patients participated in the 
study. Results: All patients had severe hypertension resistant to multiple medications; 10 patients had impaired 
renal function (serum creatinine level greater than 130 μmol/L). A total of 3 (11.5%) patients had congestive heart 
failure, and 10 (37.7%) were diabetic. Hypertension was cured in 1 (4%) patient, had improved in 23 (88.4%) 
patients, and had failed to respond to treatment in 2 (7.6%). Serum creatinine decreased significantly from 1.46 
± 0.89 to 1.35 ± 0.61 mg/dL (P<0.05). Conclusion: Percutaneous transluminal angioplasty for atheromatous 
RAS rarely “cures” hypertension, but improved blood pressure control is often achieved. 
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INTRODUCTION
Renal artery stenosis (RAS), mostly caused by atherosclerosis, 
can cause both renovascular hypertension and renal 
insufficiency.[1,2]. Treatment of RAS by surgery or balloon 
angioplasty aims at avoiding lifelong antihypertensive 
treatment and progressive renal ischemia.[1-3] The frequency 
of documented RAS varies from 0.5% to >20%, according 
to age[4] and the thoroughness of investigation,[5-7] and 
will probably increase with the increasing population 
age and the widespread use of noninvasive screening 
tests.[1,3-8] Attempts at revascularization will also increase 
because angioplasty reported to be as effective as surgery[9] 
allows treatment of older and more fragile patients. The 
efficacy and safety of  angioplasty in hypertension among 
these patients should be objectively evaluated.[9] With the 
exception of a randomized trial reported in an abstract 
form,[10]only information based on retrospective analyses is 
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available.[2,10,12,13]  We compared the 1-month blood pressure 
(BP) outcome and the incidence of complications after 
diagnostic angiography plus angioplasty (angioplasty group) 
in patients with hypertension and unilateral atherosclerotic 
RAS. The number of antihypertensive agents required to 
obtain target BP was determined, and the BP outcome 
was documented with the use of 24-h ambulatory BP 
monitoring (ABPM), an observer-independent assessment 
that improves the repeatability of BP measurement.[14] 
MATERIALS AND METHODS
Patients were referred to the participating centers 
for hypertension and unilateral atherosclerotic RAS 
documented with intravenous subtraction angiography or 
a previous arteriography. Eligible patients were men and 
women younger than 90 years of age, with diastolic blood 
pressure (DBP) readings >90 mmHg on at least three 
occasions and/or receiving antihypertensive treatment; 
patients with a history of stroke, pulmonary edema, or 
myocardial infarction in the previous 6 months were not 
included. Anatomic inclusion criteria were determined 
from the qualifying angiography immediately before 
randomization. They comprised (1) the atherosclerotic 
nature of the RAS, as inferred from renal artery and 
aortic views; (2) a reduction in arterial diameter of either 
70% without thrombosis; (3) a stenosis affecting the main 
renal artery, which had not been previously dilated; and 
(4) a functional kidney on the opposite side exhibiting a 
normal main artery or an arterial diameter reduction of 
<50%. Patients gave written informed consent before the 
qualifying angiography. 
Clinical evaluation
The creatinine clearance was estimated from the serum 
creatinine (sCR) concentration with the Cockcroft 
formula[15] and ABP was monitored over the 24 h before 
hospitalization. Patients were hospitalized for qualifying 
catheter angiography. Before randomization and at 
termination, 24-h ABP was measured with SpaceLabs 5300 
or 90207 (SpaceLabs, Inc.) or Colin ABPM 630 (Colin 
Medical Instruments) monitoring devices programmed 
to record BP every 15 min during the day and every 30 
min during the night. The same monitor was used on the 
same arm of  each patient before randomization and at 
termination. Sitting BP was also measured with a mercury 
sphygmomanometer during each visit to compare DBP 
readings with oscillometric and ambulatory determinations. 
Technique
The femoral approach was used in all cases less than 1 month 
after selective angiography. The standard technique involved 
the placement of a 7-F introducer sheath into the femoral 
artery and negotiation of the stenosis by using a wire, and 
stents (EXPRESS (Boston Scientific Co), HERCULING 
(Abbot Vascular Co), and HIPPOCAMPUS (Invatec Co)) 
were positioned coaxially through a 7-F guiding catheter 
(RDC), with its tip in the renal ostium. Then 10–15 mL 
of the contrast material (Iopramide [150 mg of iodine 
per milliliter] was injected into the guiding catheter by 
using a side-arm adaptor to obtain fine adjustment of the 
stent position before deployment. In ostial lesions, stents 
were deliberately deployed so that they projected 1 mm 
into the aortic lumen. The optimal final stent diameter 
was determined by measuring the caliber of a normal 
segment of the same renal artery. Stenosis was not routinely 
predilated. The immediate technical result was evaluated with 
angiography. Technical success was defined as a residual 
stenosis of less than 10%. All patients received 5000 units 
of heparin that was administered intra-arterially during the 
procedure, and antiplatelet therapy (aspirin, 325 mg daily, and 
plavix, 450 mg loading and 75 mg daily for 2 months). No 
patients formally received anticoagulation therapy following 
this procedure. Intra-arterial angiographic follow-up was not 
performed routinely in this high-risk patient group. Clinical 
follow-up for 6–12 months was used to guide management. 
If patients showed clinical evidence of relapse following the 
initial favorable outcome, angiography was performed. Age, 
gender, pre- and postprocedure creatinine levels and ejection 
fraction, systolic and diastolic blood pressure recording, and 
history of DM were recorded. All patients were examined 
once within 3 weeks of the procedure. In most patients, 
blood pressure and sCr values were also available for as many 
as 3 months prior to the procedure. Renal impairment was 
classified as improved if the sCr level decreased by 10% or 
more and stable if it was within 10% of the preprocedure 
level. Renal impairment with an increase of more than 10% 
was classified as a failure. Hypertension was classified as 
cured if all antihypertension medication was stopped and 
diastolic blood pressure returned to less than 90 mmHg. 
Criteria for improvement were either diastolic blood pressure 
less than 90 mmHg without the increased medication dose 
or between 90 and 110 mmHg with a decrease greater 
than 15 mmHg and no increase in the medication dose. All 
other possibilities constituted a failure. Complications were 
evaluated by reviewing the renal angiography reports for 
immediate procedural complications and the case notes 
for delayed procedure-related and clinical complications. 
Data analysis
We intended to enroll 27 patients. This sample size would 
have allowed 85% power to detect a 10 mmHg difference 38 Journal of Cardiovascular Disease Research Vol. 2 / No 1
Adel et al.: Clinical efficacy of percutaneous renal revascularization
improved in 23 (88.4%) patients, and had failed to respond 
to treatment in 2 (7.8%) immediately after stenting clinically. 
Mean arterial systolic and diastolic blood pressures 
measured with Holter monitoring that recorded awake 
time, sleep time, and overall blood pressure for all patients 
who underwent stent placement for their hypertension 
(including no responders) are shown in Table 2. All 
blood pressure parameters (systolic/diastolic/mean, for 
overall, awake time, and sleep time) decreased significantly 
immediately after the intervention. After intervention in the 
female group, there was no significant difference for the 
decrease in mean/diastolic pressure especially in awake and 
sleep time (P > 0.05). In 46.1% of the patients, the mean 
arterial blood pressure control was improved after mean 
follow-up; it remained unchanged in 43% and deteriorated 
in 11% patients. Patients with diabetes also had improved 
blood pressure control [Table 3]. 
Renal impairment 
Serum creatinine decreased significantly from 1.46 ± 
0.89 to 1.35 ± 0.61 mg/dL (P<0.05). Renal impairment 
improved in 12 (46.1%) patients (>10% decrease in the Cr 
concentration from baseline), stabilized in 12 (46.1%; 0–9% 
change in the Cr concentration), and failed to respond to 
treatment in 2 (7.8%; 10% increase in the Cr concentration). 
However, some important subgroup changes were noted. 
Four (11%) patients had a deterioration of the renal 
function during 3 months after stenting, leading to chronic 
renal failure without leading to dialysis. Subgroup analysis 
in the improved renal function showed no significant 
change in sCr in patients with a normal renal function at 
baseline, but there was a significant (P < 0.05) decrease in 
sCr in patients with moderate and severe renal dysfunction, 
respectively [Table 4]. The more severe the renal dysfunction 
at baseline, the more the patients benefited from the 
in diastolic ABP at termination between the two groups, 
with a type I error of 5%. SPSS software was used for 
statistical analysis. Proportions were compared by the 
Proc Freq procedure and quantitative variables by the Proc 
T-test procedure.
RESULTS 
Patients
Twenty-seven (18 men, 9 women; average age, 62.6 
years; age range, 90–21 years) consecutive patients with 
angiographically proven atherosclerotic RAS were referred 
to the Angiography Department of Imam Hospital for 
renal arterial stenting treatment during a 1-year period from 
June 2008 to December 2009. 
All patients had a history of severe hypertension with 
poor response to drug therapy; 10 (37.7%) patients had an 
impaired renal function (sCr level greater than 130 μmol/L 
or 1.4 mg/dL), 3 (11.5%) had congestive heart failure, and 
10 (37.7%) were diabetic. Primary stent placement was 
attempted by a single operator (there is one peripheral 
interventionalist in our center) in 27 severe RAS cases 
[Table 1].
Technical results
Technical success (primary patency) was achieved in 26 
(96.2%) patients. Reasons for technical failure were failure 
to cross the stenosis with a guide wire in one patient. 
Clinical outcome
One case was omitted from the study because of technical 
failure. Hypertension was cured in one (3.8%) patient, had 
Table 1: Baseline clinical characteristics in patients before renal angioplasty
Total [n = 26; n (%)] Men [n = 17; n (%)] Women [n = 9; n (%)]
Age (years) 62.6 64 60
Diabetes  10 (37.7) 7 (41) 3 (33)
Current smoker  3 (11) 3 (17) 0 (0)
Heart failure  3 (11.5) 1 (5.5) 2 (22.5)
Duration of hypertension > 5 year  20 (77) 15 (88) 5 (55)
Baseline creatinine > 1.3 mol/L  10 (37.7) 8 (47) 2 (22)
MSBP awake > 135 mmHg  26 (100) 17 (100) 9 (100)
MSBP sleep > 120 mmHg  23 (88.5) 15 (88) 8 (88.5)
MDBP awake > 80 mmHg  25 (96) 17 (100) 8 (88.5)
MDBP sleep > 70 mmHg  23 (88.5) 15 (88) 8 (88.5)
MABP awake > 75 mmHg  26 (100) 17 (100) 9 (100)
MABP sleep > 65 mmHg  26 (100) 17 (100) 9 (100)
Variables are given as number (%) or median values. MSBP, Mean systolic blood pressure; MDBP, Mean diastolic blood pressure; MABP, Mean arterial blood pressure.39 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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intervention: improved mean sCr concentrations were 
seen in 43.6% of patients with a normal renal function, 
44.6% of patients with moderate impairment, and 100% 
of those with a severely impaired renal function. Patients 
without diabetes mellitus had higher sCr concentrations 
at baseline compared with patients with diabetes mellitus 
(1.58 ± 1.08 mg/dL versus 1.25 ± 0.3 mg/dL; P < 0.05). 
The decrease in sCr was significant in the subgroup of 
patients without diabetes mellitus (1.58 ± 1.08 to 1.41 ± 
0.7 mg/dL; P < 0.05), whereas the sCr decrease was not 
significant in diabetic patients (1.25 ± 0.32 to 1.23 ± 0.38 
mg/dL; P > 0.05).
Patients with severe nephrosclerosis and diabetes mellitus 
needed the greatest number of antihypertensive drugs and 
had the highest blood pressure levels at baseline. Procedure-
related complications occurred in 2 (7.7%) of the 26 cases. 
The major complications included one femoral artery false 
aneurysm that was successfully treated with compression, 
and one patient had acute renal failure.
DISCUSSION
In patients with hypertension and RAS, renal artery 
angioplasty should ideally provide a cure for hypertension, 
that is, normal BP without treatment. Angioplasty allows 
hypertension cure in 50% of patients with fibromuscular 
RAS, and complications are not frequent in this group. 
However, the cure rate is lower and the incidence of 
complications higher among patients with atherosclerotic 
Table 2: Holter monitoring of overall, awake, and sleep systolic blood pressure, diastolic blood pressure, and mean 
arterial pressure, before and after stenting in patients with renal artery stenosis
P-value After stenting Before stenting                         Group 
0.014 178 ± 27 189 ± 26 Overall* SBP
0.017 178.5 ± 29.9 188.2 ± 26.4 Awake
0.41 150.8 ± 26.1 157.6 ± 27.6 Sleep
0.001 97.2 ± 16.2 113.5 ± 24.2 Overall DBP
0.001 97.6 ± 16.2 135 ± 24 Awake
0.004 81.7 ± 12.6 91.04 ± 15.2 Sleep
<0.001 115.8 ± 20 130.6 ± 23.8 Overall Mean BP
<0.001 115.8 ± 20 130.84 ± 24 Awake
<0.029 98.2 ± 16.2 106.3 ± 16.6 Sleep
*Overall blood pressure is a mean of all blood pressure recordings during awake and sleep time by measured by Holter monitoring. SBP, Systolic blood pressure; DBP,  
Diastolic blood pressure; mean BP, Mean arterial pressure.
Table 3: Holter monitoring of systolic, diastolic, and mean arterial pressure before and after renal artery stenting in 
patients with and without diabetes
P-value Without diabetes (n = 16) P-value With diabetes (n = 10) Baseline
After stent Before stent After stent Before stent
0.001 176.4 ± 32 187.1 ± 29 0.01 183.2 ± 25.1 192.35 ± 19.2 Overall* SBP
0.001 176.4 ± 32 186.2 ± 30 0.01 182.2 ± 26 191.8 ± 19.8 Awake
0.02 149 ± 29 156.7 ± 27 0.17 154 ± 18 159.6   ± 30 Sleep
0.01 99.3 ± 17 169.9 ± 28 0.06 97.4 ± 14.4 107.5 ± 13 Overall DBP
0.01 99.3 ± 17 116.9 ± 28 0.06 95.4 ± 14 107.5 ± 13.5 Awake
0.05 81 ± 13 90.2 ± 14 0.2 82.8 ± 10 92.4 ± 17 Sleep
0.003 115.6 ± 22 133.3 ± 28 0.02 116.3 ± 16 125.8 ± 12 Overall MAP
0.003 115.5 ± 5 132.9 ± 7 0.02 116.3 ± 17 125.8 ± 12 Awake
0.1 97.5 ± 45 104.2 ± 4 0.03  99.4 ± 13 110.11 ± 17 Sleep
*Overall blood pressure is a mean of all blood pressure recordings during awake and sleep time  measured by Holter monitoring.
Table 4: Mean range of serum creatinine improvement before and after renal artery stenting
Improvement >10% from  
baseline Cr among patients
After stenting Before stenting Mean of Cr  
(mg/dL)
Renal impairment
43.7% (n = 16, P>0.05) 0.19 ± 1.01 0.14 ± 1.06 <1.2 Mild
44.6% (n = 7, P<0.05) 0.6 ± 1.8 0.8 ± 1.8 1.2–3 Moderate
100% (n = 3, P<0.05) 0.2 ± 3.05 0.4 ± 4.2 >3 Severe40 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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RAS.[13,16] Atherosclerotic patients more frequently suffer 
from technical failures or subsequent restenosis than 
those with fibromuscular RAS.[13,17] They frequently have 
preexisting primary hypertension, structural changes in 
large arteries, or an impaired renal function that limit the 
efficacy and safety of angioplasty.[2,3,7,13,16] Retrospective 
series report that the usual BP outcome after angioplasty 
for atherosclerotic RAS is improvement, that is, a 
reduction in BP levels and/or in the required number of 
antihypertensive agents.[2,13] There are no uniform criteria 
for assessing the improvement, however, and it may be 
spontaneous or a consequence of alterations in the drug 
choice and dosage.[3,9,13] There is therefore a need for more 
trials to assess risks and benefits associated with angioplasty 
in atherosclerotic RAS. The “Scottish and Newcastle Renal 
Artery Stenosis  Collaborative Group” reported in an 
abstract form a trial of angioplasty versus medical therapy 
in patients with bilateral or unilateral atherosclerotic RAS.[10] 
In the bilateral RAS group (n = 28), the drop in systolic BP 
was significantly greater after angioplasty than after medical 
therapy, but diastolic BP and creatinine levels did not differ 
between the two groups after 24 months. In the unilateral 
RAS group (n = 27), there was no significant difference in 
BP levels after angioplasty or medical therapy. The main 
outcome variable used was OBP, and no detail was provided 
concerning treatment standardization. 
In our study on percutaneous stent-supported angioplasty 
of severe atherosclerotic RAS, we observed the stabilization 
of the renal function and substantial improvement in the 
blood pressure control at a mean follow-up of 1 month. 
The observed 11% deterioration of the renal function 
during follow-up is comparable to previous reports.[18-39] 
However, in contrast to Dorros et al.’sstudy,[24,25,31] which 
found a deteriorated renal function in 47% of patients 
with a baseline sCr concentration of >2 mg/dL, and like 
Zeller et al.,[26] we saw a higher proportion of patients with 
improved or unchanged sCr among those with the worst 
renal function at baseline.
The 11% rate of the deteriorated blood pressure control 
during follow-up was remarkably low, which may be 
explained by the blood pressure acquisition method in 
this study. Blood pressure data were exclusively obtained 
using ambulatory 24-h blood pressure recordings. In our 
opinion, this type of blood pressure data is more reliable 
compared to the incidental blood pressure measurements 
used in all other published studies.[40-47]
We found an improved renal function that was similar to 
that reported by van de Ven et al.,[22,28] Iannone et al.,[25] 
Dorros et al.,[24,25,31] and Zeller et al.[39] The US Multicenter 
Registry[25] demonstrated a significant decrease in the 
sCr concentration in an unselected study population 
comparable to ours (1.7 ± 1.1 to 1.3 ± 0.8 mg/dL after 4 
years), which is similar to our data.
The present trial was targeted toward patients with 
unilateral RAS because such cases are more frequent and 
revascularization is easier, safer, and more likely to result 
in a favorable BP outcome than in cases with bilateral 
RAS or RAS affecting a solitary kidney.[21] Patients with 
fibromuscular RAS were not included because good 
evidence is already available that the benefits of angioplasty 
outweigh the risks in such patients.[13] It is difficult to 
differentiate patients with primary hypertension associated 
with RAS from those having hypertension secondary to 
RAS, that is, renovascular hypertension.[1,3] To increase the 
likelihood of our patients having renovascular hypertension, 
they were selected on the basis of high-grade stenosis (renal 
artery diameter reduction 75%) or a stenosis of 60% plus a 
positive lateralizing test. Patients had been screened for RAS 
on the basis of poor efficacy and/or tolerance of previous 
antihypertensive regimen and referred to the participating 
centers because a unilateral atherosclerotic RAS was 
present. Although those with refractory hypertension were 
not included for safety reasons, patients in this trial are 
representative of the population of cases with unilateral 
atherosclerotic RAS in whom renal revascularization may 
be considered.[1,3] In real life, the early use of a combination 
of diuretics and angiotensin-converting enzyme inhibitors 
might have resulted in adequate BP in a larger number of 
patients. To avoid the biases, poor repeatability, and lack 
of precision associated with Office Blood Pressure(OBP) 
determination, therapeutic decisions were based on the 
average of three measurements, using a semiautomatic 
device, and the outcome was assessed by 24-h ABP 
monitoring. Mean ABP levels, including sleep time BP 
readings, were lower than mean OBP levels, as expected. 
The difference between ABP and OBP levels was 150/70 
mmHg (systolic/diastolic) at randomization in our patients, 
a difference comparable to that reported at the first visit 
(120/90 mmHg) in the 50 hypertensive patients analyzed 
by Bottini et al.[14] The mean ABP levels in the two groups 
were similar at termination, although the drop in diastolic 
OBP levels was higher in the control group than in the 
angioplasty group. These results emphasize the need for 
an outcome assessment made independent of investigators 
when blinding is not possible. 
Although mean ABP levels were very similar in both 
groups at termination, angioplasty allowed an easier BP 
control than medication alone. Treatment scores were 
higher in the control group than in the angioplasty group, 41 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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antihypertensive agents being required at termination 
for all control patients but not for 6 of the 23 allocated 
to angioplasty (26%). Moreover, 7 of 25 (28%) patients 
in the control group developed refractory hypertension 
leading to secondary angioplasty within 6 months. The high 
BP levels and treatment scores that these seven patients 
exhibited immediately before secondary angioplasty were 
included in the analysis. Guidelines for early interruption 
were established at the design stage of the study and stated 
that patients should be withdrawn for safety reasons if 
hypertension were refractory or there were intolerable drug-
induced side effects. These guidelines necessitated an on-
treatment analysis, with seven patients in the control group 
having a follow-up of <6 months. We did not perform an 
intention-to-treat analysis at 6 months because this would 
have overestimated the drop in BP in the control group, the 
BP effects of angioplasty being added to those of medication 
in the seven patients developing refractory hypertension and 
switching to angioplasty. It is possible that their 6-month 
ABP levels and treatment score would have been even 
higher if early termination had not been allowed, raising 
the possibility that the BP difference between control and 
angioplasty groups was underestimated because of safety 
dispositions. The BP effects of the randomized therapeutic 
regimen, medication, and angioplasty were only compared in 
the short term, the experimental period lasting for 6 months 
or less. However, mean OBP levels and the proportion of 
patients given antihypertensive treatment were similar 1 year 
after randomization in the control and angioplasty groups, 
confirming that the BP-lowering effect of angioplasty in 
the short and medium terms is limited in atherosclerotic 
RAS. Although the patients were selected on the basis of 
high-grade stenosis (>75%) and/or a positive lateralizing 
test, only a minority of them had true renovascular 
hypertension, that is, a form of hypertension fully reversible 
after revascularization.[1,3] In addition to frequently associated 
primary hypertension and an impaired renal function, 
individuals with atherosclerotic RAS lose the ability, with 
increasing age, to reverse the structural vascular changes 
associated with secondary hypertension.[45] This underlines 
the need for the early detection of RAS to allow angioplasty 
in patients with a short duration of hypertension.[3,4,23]
The complication rate in our group of patients undergoing 
angioplasty was substantial (6 of 23, or 26%) and higher 
than that in many retrospective series.[13,16] Clinicians 
involved in the present trial might have used a low threshold 
to define the presence of a complication. However, they 
probably applied the same criteria to patients in both 
treatment groups, and angioplasty was more frequently 
associated with complications than diagnostic angiography 
alone. It is also possible that complication rates have been 
underestimated in some series because they were not 
documented prospectively in a standardized clinical report 
form. In the largest retrospective series of angioplasty for 
atherosclerotic RAS, mechanical complications and acute 
renal failure (generally reversible) occurred in 26% and 14% 
of procedures, respectively.[21] In a prospective randomized 
trial comparing angioplasty with surgery in atherosclerotic 
RAS,[9] there were major and minor complications in 5 and 
11 of the 29 patients in the angioplasty group (17% and 
48%), respectively. In the present trial, most immediate 
complications were mild and transient. 
CONCLUSION
In summary, previous uncontrolled and unblinded 
assessments of angioplasty overestimated its potential for 
lowering BP [Table 5]. Using a prospective, randomized, 
open, blinded outcome (PROBE) design, we found that 
angioplasty made the BP control easier in the short term 
but was more frequently associated with complications 
than conservative management in patients with unilateral 
atherosclerotic RAS. Most patients undergoing angioplasty 
still needed antihypertensive agents 6 or 12 months after the 
procedure. The reduction in treatment required by patients 
undergoing angioplasty should therefore be weighed against 
the risks of complications and restenosis. Previously 
reported data and this evidence suggest that patients with 
RAS and little or no renal insufficiency should be offered 
angioplasty if the underlying disease is fibromuscular 
dysplasia,[13] in cases with recurrent pulmonary edema,[47] 
and in those with refractory hypertension. Patients with 
atherosclerotic RAS also have or develop atherosclerotic 
Table 5: Summary
What is known about this topic
• The usual BP outcome after angioplasty for atherosclerotic RAS is improvement, that is, a reduction in BP levels and/or in the required 
number of antihypertensive agents.[2,13]
• However, the cure rate for hypertension is lower and the incidence of complications higher among patients with atherosclerotic  
RAS.[13,16]
What this study adds
• Using a prospective, randomized, open, blinded outcome (PROBE) design, renal angioplasty made BP control easier in the short term but 
was more frequently associated with complications than conservative management in patients with unilateral atherosclerotic RAS.
• Most patients undergoing angioplasty still needed antihypertensive agents 6 or 12 months after the procedure.42 Journal of Cardiovascular Disease Research Vol. 2 / No 1
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plaques or stenosis on extrarenal arteries. In such patients 
with a stable renal function and controllable hypertension, 
the effects of angioplasty on the long-term cardiovascular 
outcome should be compared with those of conservative 
treatment by using antihypertensive and lipid-lowering 
agents. Until such a comparison becomes available, the 
immediate risks and the potential long-term benefits of 
angioplasty should be weighed for each individual patient, 
possibly by including patient preference. 
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